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Background:  Individuals  50–64 years  of age  have  reduced  immune  responses  to inﬂuenza  vaccines.  The
current  study  examined  whether  a high-dose  inactivated  trivalent  inﬂuenza  vaccine  (IIV3-HD)  might
improve  immune  responses  over  a standard-dose  inactivated  inﬂuenza  vaccine  (IIV3-SD)  in  this  age
group.
Methods:  This  was  a  multicenter,  observer-blinded,  randomized,  active-controlled  phase  II trial. Adults
50–64  years  of  age  were  randomized  1:1  to  receive  IIV3-HD  or IIV3-SD.  Hemagglutination  inhibition
titers  were  measured  before  and 28  days  after  vaccination.  Reactogenicity  was  recorded  for  7 days  after
vaccination  and  adverse  events  for  28 days.
Results: 148  participants  received  IIV3-HD  and  152  received  IIV3-SD.  For  all vaccine  strains,  day  28  geo-
metric  mean  hemagglutination  inhibition  titers  were  signiﬁcantly  higher  in  the  IIV3-HD  group  than  in the
IIV3-SD  group  (geometric  mean  titer  ratio  [95%  conﬁdence  interval  (CI)]  =  1.43  [1.04–1.97]  for  A/H1N1,
1.65  [1.21–2.25]  for A/H3N2,  and  1.60  [1.23–2.08]  for  B). Seroconversion  rates  were  signiﬁcantly  higher
in  the  IIV3-HD  group  than  in the  IIV3-SD  group  for strains  A/H3N2  and  B but  not  A/H1N1  (difference  [95%
CI]  =  13.5%  [4.76–22.0]  for  A/H3N2,  23.1%  [11.7–33.6]  for B,  and  −0.2% [−9.66  to 9.18] for  A/H1N1).  The
post-vaccination  seroprotection  rate  was  signiﬁcantly  higher  in  the  IIV3-HD  group  than  in  the IIV3-SD
group  for  strain  B  but  not  for strains  A/H1N1  or A/H3N2  (difference  = 9.1%  [2.95–15.7]  for  B, 2.0%  [−0.907
to  5.68]  for  A/H1N1,  and  0.6% [−3.14  to  4.43]  for A/H3N2).  Reactogenicity  was  higher in  the  IIV3-HD
group  than  in the IIV3-SD  group,  but  reactions  were  mostly  of low  intensity,  transient,  and  self-limited.
Rates  of  unsolicited  adverse  events  were  similar  between  groups.  No  serious  AEs, AEs  leading  to  early
withdrawal,  or  deaths  were  reported.
Conclusions:  The  study  suggests  that in  adults  50–64  years  of  age, IIV3-HD  may improve  immunogenicity
compared  to IIV3-SD  while  maintaining  an  acceptable  safety  proﬁle.© 2015  The  Authors.  Publis
Abbreviations: AE, adverse event; CI, conﬁdence interval; GMT, geometric mean titer
nﬂuenza vaccine; IIV3-HD, high-dose trivalent inactivated inﬂuenza vaccine; IIV3-SD, st
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. Introduction
Persons ≥50 years of age are at increased risk for serious com-
lications of inﬂuenza, such as pneumonia, exacerbation of chronic
eart or lung disease, and death [1,2]. However, vaccine efﬁcacy and
ntibody responses are substantially reduced in older adults due
o immunosenescence [3]. This loss in immune response is well
stablished for adults ≥65 years of age, but immune responses to
nﬂuenza vaccination are also weaker in adults 50–64 years [4–6].
Increasing the dose of hemagglutinin (HA)3 per vaccine strain is
ne approach for improving the immune response in older adults
3]. A high-dose trivalent inactivated inﬂuenza vaccine (IIV3-HD)
as been licensed in the US for persons aged ≥65 years based on its
bility to induce a stronger immune response than a standard-dose
rivalent inactivated inﬂuenza vaccine (IIV3-SD) in this population
7–10]. IIV3-HD contains 60 g HA per viral strain, a 4-fold increase
ver IIV3-SD. A recent phase IIIb/IV study in more than 30,000 par-
icipants conﬁrmed that in persons ≥65 years, IIV3-HD induced
uperior antibody responses and provided better protection against
aboratory-conﬁrmed inﬂuenza illness than IIV3-SD [11]. However,
hether the IIV3-HD might also provide improved protection in
ersons 50–64 years of age has not been established. In this article,
e describe the results of a phase II study investigating the safety
nd immunogenicity of the IIV3-HD compared to IIV3-SD in adults
0–64 years of age.
. Methods
.1. Study design and ethics
This was a multicenter, modiﬁed double-blind (observer
linded), randomized, active-controlled phase II trial in adults
0–64 years of age (ClinicalTrials.gov no. NCT01258595). The study
as conducted at four centers in the United States between
ovember 15, 2010 and January 14, 2011. The objective of the
tudy was to describe the immunogenicity and safety of IIV3-HD
ompared to IIV3-SD. The study was approved by a central insti-
utional review board (Quorum Review) and was  conducted in
ccordance with the Declaration of Helsinki, International Confer-
nce on Harmonisation guidelines for Good Clinical Practice, and
ocal and national laws. All participants provided written informed
onsent.
.2. Participants
Medically stable adults 50–64 years of age were considered for
nrollment. Participants were excluded if they had received a sea-
onal or pandemic inﬂuenza vaccine in the past 6 months; received
lood or blood-derived products in the previous 3 months; received
r planned to receive any vaccine before or after 4 weeks of trial
accination; participated in another clinical trial investigating a
accine, drug, medical device, or medical procedure in the 4 weeks
receding the trial vaccination; a known or suspected congeni-
al or acquired immunodeﬁciency; received immunosuppressive
herapy within the previous 6 months; a neoplastic disease or any
ematologic malignancy; a bleeding disorder or receipt of anti-
oagulants in the previous 3 weeks; a history of Guillain-Barré
yndrome; a systemic hypersensitivity to eggs, chicken proteins,
r any of the vaccine components; a history of a life-threatening
eaction to the IIV3-SD or to a vaccine containing any of the same
ubstances; or were seropositive for human immunodeﬁciency
irus, hepatitis B, or hepatitis C. Women  could not be pregnant or
reastfeeding.ne 33 (2015) 7188–7193 7189
2.3. Study conduct
Participants were randomized 1:1 to receive a single intramus-
cular injection of the 2010–2011 Northern Hemisphere formulation
of IIV3-HD (Fluzone® High-Dose) or IIV3-SD (Fluzone) into the
deltoid area. Both vaccines were manufactured by Sanoﬁ Pas-
teur (Swiftwater, PA, USA) and contained the A/California/07/2009
(H1N1), A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008 (B)
strains. To insure adequate representation of the older age group,
recruitment was  stratiﬁed to enroll participants 50–59 and 60–64
years of age in a 2:1 ratio. Randomization and allocation were con-
cealed via an interactive voice response system, which supplied a
centralized, stratiﬁed, randomization code. The participants, inves-
tigators, study site personnel, and clinical team members involved
in the trial were blinded to the vaccines administered, with the
exception of unblinded qualiﬁed study staff members who admin-
istered the vaccines and the corresponding site monitors. The
unblinded qualiﬁed study staff did not participate in the collec-
tion of safety data. Blood was  collected at randomization and at the
second visit (day 28, allowed range, days 28–35).
2.4. Study endpoints
Immunogenicity endpoints included the geometric mean
hemagglutination inhibition (HAI) titer (GMT) on day 0 and 28;
day 28/day 0 GMT  ratio; and seroconversion and seroprotection
rates for each treatment group. Seroprotection was deﬁned as an
HAI titer ≥40 and seroconversion was  deﬁned as either (i) a pre-
vaccination HAI titer <10 and a post-vaccination HAI titer ≥40 or
(ii) a pre-vaccination HAI titer ≥10 and a ≥4-fold increase in HAI
titer at day 28. HAI assays were performed as previously described
[12] by personnel blinded to vaccine assignment. The HAI titer was
the reciprocal of the highest dilution resulting in complete inhibi-
tion of hemagglutination. The lower limit of quantitation for the
assay was  a titer of 10. Samples with titers below the lower limit
of quantitation were assigned a titer of 5, and samples with titers
above the upper limit of quantitation (10,240) were assigned a titer
of 10,240.
Safety endpoints included the occurrence, nature, duration,
intensity, action taken, and relationship to vaccination of any
immediate unsolicited systemic adverse event (AE), solicited reac-
tion, unsolicited AE, or serious adverse events (SAE). AEs and SAEs
were recorded according to International Conference on Harmoni-
sation Guideline for Clinical Safety Data Management: Deﬁnitions
and Standards for Expedited Reporting and were coded using Med-
DRA version 13.0 (MedDRA MSSO, McLean, VA, USA). Solicited
systemic reactions (fever, headache, malaise, myalgia, and shiver-
ing) and solicited injection-site reactions (pain, erythema, swelling,
induration, and ecchymosis) were recorded by participants on diary
cards for 7 days following vaccination. Other non-serious unso-
licited AEs were recorded by patients for 28 days after vaccination.
SAEs were recorded by investigators for 28 days after vaccina-
tion. AEs of special interest were reported and analyzed as SAEs
and included new onset of Guillain-Barré syndrome, Bell’s palsy,
encephalitis/myelitis, optic neuritis, Stevens-Johnson syndrome, or
toxic epidermal necrolysis. Immediate AEs were deﬁned as AEs
occurring within 30 min  after vaccination.
2.5. Statistical analysis
All calculations were performed using SAS version 9.1 (SAS Insti-
tute, Cary, NC). Missing data were not replaced. As this was a pilot
study, sample size was not based on power calculations but rather
was arbitrarily selected to provide initial estimates of immuno-
genicity and safety.
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Table 1
Baseline characteristics.
Characteristic IIV3-HD
(n = 148)
IIV3-SD
(n = 152)
Sex, n (%)
Male 50 (33.8) 56 (36.8)
Female 98 (66.2) 96 (63.2)
Age (y), mean ± standard deviation 57.6 ± 4.4 57.7 ± 4.1
Race, n (%)
Caucasian 117 (79.1) 126 (82.9)
Black 28 (18.9) 22 (14.5)
Hispanic 2 (1.4) 4 (2.6)
Other 1 (0.7) 0 (0.0)
Any signiﬁcant medical history 99 (66.9) 100 (65.8)
Previous inﬂuenza vaccination 124 (83.8) 125 (82.2)
Values are for the safety analysis set.
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Table 3
Post-vaccination (day 28) immunogenicity comparisons.
Comparison A/H1N1 A/H3N2 B
Ratio of GMTs 1.43 (1.04, 1.97) 1.65 (1.21, 2.25) 1.60 (1.23, 2.08)
Seroprotection
difference
2.0  (−0.907, 5.68) 0.6 (−3.14, 4.43) 9.1 (2.95, 15.7)
Seroconversion
difference
−0.2  (−9.66, 9.18) 13.5 (4.76, 22.0) 23.1 (11.7, 33.6)
The ratio of GMTs was  deﬁned as GMTIIV3-HD/GMTIIV3-SD. Seroprotection and sero-
conversion differences were calculated by subtracting the IIV3-SD value from the
fold for the A/H1N1 and A/H3N2 strains and by approximately 4-
to 6-fold for the B strain (6.3-fold for IIV3-HD, 3.9-fold for IIV3-SD)
(Table 2). For all vaccine strains, day 28 GMTs were signiﬁcantly
T
I
H
t
≥
wImmunogenicity endpoints were assessed in the full analysis set,
hich comprised all participants who received at least one dose of
tudy or control vaccine. Results were veriﬁed in the per-protocol
nalysis set, deﬁned as all participants who met  all eligibility crite-
ia, received at least one dose of study or control vaccine, received
accine according to randomization, provided paired pre- and post-
ose serology samples, and provided the post-dose serology sample
n the proper time window. The conﬁdence intervals (CIs) for GMTs
nd the GMT  ratios were calculated based on the t distribution and
he assumption that the log(HAI titer) followed a normal distribu-
ion. The GMT  was considered signiﬁcantly different if the 95% CI
f the IIV3-HD/IIV3-SD ratio did not include 1. Seroconversion and
eroprotection rates were considered signiﬁcantly different if the
5% CIs of the difference (IIV3-HD minus IIV3-SD), computed using
he Wilson Score without continuity correction, did not include 0.
Safety endpoints were assessed in the safety analysis set, which
as deﬁned as all participants who received the study or con-
rol vaccine. The 95% CIs for percentages were constructed by
he Clopper-Pearson method. No formal statistical tests were per-
ormed for safety measures.able 2
mmunogenicity.
Measure Strain Day 
GMT A/H1N1 0 
28  
A/H3N2 0  
28  
B 0  
28  
GMT  ratio A/H1N1 28/0 
A/H3N2 28/0 
B  28/0 
Seroconversion A/H1N1 28/0 
A/H3N2 28/0 
B  28/0 
Seroprotection A/H1N1 0 
28  
A/H3N2 0  
28  
B 0  
28  
AI titers were measured before vaccination (day 0) and at the second study visit, 28–35 
iter/day  0 titer ratios. Seroprotection was deﬁned as a HAI titer ≥40 and seroconversion
40  or pre-vaccination HAI titer ≥10 and ≥4-fold increase in HAI titer. Values are for th
ere  similar for the per-protocol analysis set (data not shown).IIV3-HD value. All values are for the full analysis set and with treatment accord-
ing to randomization. 95% CIs are shown in brackets. Results were similar for the
per-protocol analysis set (data not shown).
3. Results
3.1. Participants
Between November 15, 2010 and December 10, 2010, a total of
300 participants were enrolled and were randomized to be vacci-
nated with IIV3-HD (n = 148) or IIV3-SD (n = 152). All participants
were vaccinated as randomized. Two dropouts occurred: one sub-
ject in the IIV3-HD group was  lost to follow-up before the end of
the study and one in the IIV3-SD group voluntarily withdrew before
the end of the study for a reason other than an AE. In addition, 12
participants in the IIV3-HD group and 8 in the IIV3-SD group were
excluded from the per-protocol analysis set because of protocol
violations (Supplemental Table 1).
Baseline characteristics were similar in the two  groups (Table 1).
Both groups included nearly twice as many women  as men. Mean
ages were between 57 and 58 years. More than 80% of the partici-
pants in each group had previously received inﬂuenza vaccination.
3.2. Immunogenicity
Vaccination with either vaccine increased GMTs more than 10-higher in the IIV3-HD group than in the IIV3-SD group (Table 3).
IIV3-HD IIV3-SD
(n = 148) (n = 152)
40.5 (30.0, 54.5) 28.8 (21.8, 38.1)
1067 (868, 1312) 745 (585, 948)
36.4 (28.0, 47.4) 41.4 (31.4, 54.6)
936 (745, 1176) 567 (459, 699)
27.4 (22.4, 33.6) 28.9 (23.5, 35.5)
203 (171, 241) 127 (104, 154)
21.8 (16.1, 29.6) 21.2 (15.8, 28.4)
22.0 (17.2, 28.1) 12.0 (9.21, 15.5)
6.27 (5.16, 7.62) 3.91 (3.17, 4.83)
77.9 (70.3, 84.4) 78.1 (70.7, 84.5)
89.0 (82.7, 93.6) 75.5 (67.8, 82.1)
64.1 (55.8, 71.9) 41.1 (33.1, 49.3)
50.3 (42.0, 58.7) 41.4 (33.5, 49.7)
100.0 (97.5, 100.0) 98.0 (94.3, 99.6)
50.3 (42.0, 58.7) 51.3 (43.1, 59.5)
98.6 (95.1, 99.8) 98.0 (94.3, 99.6)
45.6 (37.4, 54.0) 46.7 (38.6, 55.0)
96.6 (92.1, 98.9) 87.4 (81.0, 92.3)
days after vaccination. The GMT  ratio was the geometric mean of individual day 28
 as a pre-vaccination (day 0) HAI titer <10 and post-vaccination (day 28) HAI titer
e full analysis set and with treatment shown according to randomization. Results
C.A. DiazGranados et al. / Vacci
Fig. 1. Solicited reactions. The proportion of participants reporting solicited
injection-site reactions (top) and systemic reactions (bottom) within 7 days of vac-
cination are shown for the IIV3-HD (HD) and IIV3-SD (SD) groups. Values are for the
safety analysis set. Erythema, swelling, induration, and ecchymosis were consid-
ered  grade 1 if 25–50 mm,  grade 2 if 51–100 mm,  and grade 3 if >100 mm.  Fever
was  considered grade 1 if 38.0–38.4 ◦C (100.4–101.1 ◦F), grade 2 if 38.5–38.9 ◦C
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(101.2–102.0 F), and grade 3 if ≥39.0 C (102.1 F). All other solicited reactions were
onsidered grade 1 if they did not interfere with activities, grade 2 if they caused
ome interference with activities, and grade 3 if they prevented daily activities.
eroconversion rates were signiﬁcantly higher in the IIV3-HD group
han the IIV3-SD group for the A/H3N2 (89.0% vs. 75.5%) and B
trains (64.1% vs. 41.1%) but were similar for the A/H1N1 strain
77.9% vs. 78.1%). Seroprotection rates prior to vaccination were
1–51% for all strains and were similar between the IIV3-HD and
IV3-SD groups. Post-vaccination seroprotection rates were ≥98%
or the A/H1N1 (100.0% for IIV3-HD and 98.0% for IIV3-SD) and
/H3N2 strains (98.6% for IIV3-HD and 98.0% for IIV3-SD) and were
ot signiﬁcantly different between the IIV3-HD and IIV3-SD groups.
or the B strain, the seroprotection rate was signiﬁcantly higher
n the IIV3-HD group (96.6%) than in the IIV3-SD group (87.4%).
esults stratiﬁed by age group are shown in Supplemental Table 2.
.3. Safety and tolerability
More participants in the IIV3-HD group than in the IIV3-SD
roup reported solicited injection-site reactions (76.9% [113/147]
s. 57.2% [87/152]) and solicited systemic reactions (63.9% [94/147]
s. 48.0% [73/152]) (Table 4). The most common injection-site
ite reaction was pain and the most common solicited systemic
eactions were myalgia, headache, and malaise. Most solicited
eactions were grade 1 or 2, occurred within the ﬁrst 3 days after
accination, and resolved within 1 week of the vaccination (Fig. 1
nd Supplemental Tables 3 and 4). One grade 3 solicited injection-
ite reaction was reported by a participant in the IIV3-HD group
grade 3 injection-site pain). The participant was  treated withne 33 (2015) 7188–7193 7191
a non-steroidal anti-inﬂammatory drug and the event resolved
within 4 days. Grade 3 solicited systemic reactions were reported
by 9.5% (14/147) of participants in the IIV3-HD group and 3.3%
(5/152) of participants in the IIV3-SD group. This was mostly
due to grade 3 myalgia, which was reported for 6.8% (10/147) of
participants in the IIV3-HD group and 2.6% (4/152) of participants
in IIV3-SD group. Most grade 3 reactions required no action
(medication or healthcare provider visit) to be taken and resolved
within 7 days (data not shown).
Proportions of participants reporting at least one unsolicited
AE within 28 days of vaccination were similar in the IIV3-HD
and IIV3-SD groups (35.8% [28.1–44.1] vs. 28.3% [21.3–36.2]).
Treatment-related unsolicited AEs were reported by 15 partici-
pants in the IIV3-HD group (10.1% [5.8–16.2]) and 9 participants
in the IIV3-SD group (5.9% [2.7–10.9]).
No grade 3 unsolicited non-serious treatment-related AEs were
reported in the IIV3-SD group, but 14 were reported by six partici-
pants in the IIV3-HD group (4.1%). These AEs included grade 3 dry
mouth, ocular hyperemia, throat irritation, chest discomfort, cough,
dyspnea, gastroenteritis, numbness, tingling, sore throat, swelling
in the throat, abdominal discomfort, vomiting, and neck pain. These
events all resolved without treatment except the AE of neck pain,
for which the subject received an analgesic.
No immediate unsolicited AEs, SAEs, AEs of special interest, AEs
leading to early withdrawal from the study, or deaths were reported
in this study (Table 4).
4. Discussion
This phase II study showed that, overall, the IIV3-HD was
more immunogenic than the IIV3-SD in adults 50–64 years of age.
Despite fairly high pre-vaccination seroprotection rates, both vac-
cines substantially increased immunogenicity measures compared
to pre-vaccination. Post-vaccination HAI titers and seroconversion
rates were signiﬁcantly higher with IIV3-HD for the A/H3N2 and
B strains. For the A/H1N1 strain, HAI titers were also signiﬁcantly
higher in the IIV3-HD group, although seroconversion rates were
not signiﬁcantly different. Seroprotection after vaccination was sig-
niﬁcantly higher only for the B strain; however, for both IIV3-HD
and IIV3-SD, the seroprotection rates were >94% for both A strains,
which limited the ability to compare the rates post-vaccination.
IIV3-HD was  well tolerated. No immediate reactions, SAEs, AEs
of special interest, deaths, or unexpected events related to study
vaccine were reported. As expected, given the higher dose of anti-
gen, local and systemic reactogenicity was  greater with IIV3-HD
than with IIV3-SD. This was largely due to increased myalgia, which
was reported by about half of participants, and injection-site pain,
which was reported by about three quarters of the participants.
Also, more participants in the IIV3-HD group (4.1%) than in the
IIV3-SD group (0%) reported non-serious grade 3 treatment-related
events, although these events were all self-limited.
This study has several limitations. Most importantly, this was
a pilot study that was not powered to conclusively demonstrate
superior immune responses with IIV3-HD versus IIV3-SD in this
age group. A larger conﬁrmatory study would be required to estab-
lish superiority. In addition, the study provides limited information
on the occurrence of uncommon or rare events that could theoreti-
cally be associated with the vaccines. However, rare or uncommon
events were not detected in the phase IIIb/IV study, which included
more than 30,000 older adults [11]. Furthermore, individuals with
several medical conditions were excluded, and extrapolation of the
results to such individuals should be made with caution.
Several studies in adults have measured HAI as a correlate of pro-
tection against inﬂuenza [13–16]. These studies have shown that
titers ranging from 15 to 65 are associated with 50% protection,
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Table 4
Safety summary.
Event IIV3-HD (n = 148) IIV3-SD (n = 152)
n % (95% CI) n % (95% CI)
Immediate AE 0 0 (0.0, 2.5) 0 0 (0.0, 2.4)
Solicited reaction 130 88.4 (82.1, 93.1) 110 72.4 (64.5, 79.3)
Grade  3 14 9.5 (5.3, 15.5) 5 3.3 (1.1, 7.5)
Solicited injection-site reaction 113 76.9 (69.2, 83.4) 87 57.2 (49.0, 65.2)
Grade  3 1 0.7 (0.0, 3.7) 0 0.0 (0.0, 2.4)
Solicited  systemic reaction 94 63.9 (55.6, 71.7) 73 48.0 (39.9, 56.3)
Grade  3 14 9.5 (5.3, 15.5) 5 3.3 (1.1, 7.5)
Unsolicited non-serious AE 53 35.8 (28.1, 44.1) 43 28.3 (21.3, 36.2)
Grade  3 14 9.5 (5.3, 15.4) 5 3.3 (1.1, 7.5)
Treatment-related 15 10.1 (5.8, 16.2) 9 5.9 (2.7, 10.9)
Treatment-related grade 3 6 4.1 (1.5, 8.6) 0 0 (0.0, 2.4)
AE  leading to study discontinuation 0 0 (0.0, 2.5) 0 0 (0.0, 2.4)
SAEs  and AEs of special interesta 0 0 (0.0, 2.5) 0 0 (0.0, 2.4)
Death  0 0 (0.0, 2.5) 0 0 (0.0, 2.4)
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r
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i
f
t
a
a
d
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A
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p
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t
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[
[alues are for the safety analysis set.
a AEs of special interested included new onset of Guillain-Barré Syndrome, Bell’s P
ecrolysis.
lthough more recently, a HAI titer of 110 has been suggested to
orrespond to 50% protection in children [17]. For older adults, lit-
le information on protective HAI titers is available and whether the
enerally accepted protective titer of 40 for younger adults is appli-
able is not clear. Moreover, natural variability between individuals
eans that at any given titer, some individuals will be protected
nd some not, with the probability of protection increasing in
 continuous manner with the titer. Protection curves therefore
epresent the underlying relationship between the assay and pro-
ection rather than a single protective titer [13,18]. This is relevant
or the current study because the proportion of participants with a
aseline titer above 40 was very high in both vaccine groups, which
ay bring into question the relevance of post-vaccination immune
esponses as surrogates for protection against clinical inﬂuenza.
iven that HAI protection curves indicate increasing protection
ith increasing titers beyond any speciﬁc threshold [13,18], even
n the setting of high baseline HAI titers in both vaccine groups,
he stronger immune responses in the IIV3-HD group may  result
n better protection against inﬂuenza illness. However, this study
id not assess clinical outcomes, and whether this hypothesis is
orrect will require further study of the relationship between HAI
iters and protection against inﬂuenza in older individuals and the
alue of these immune readouts as surrogates of inﬂuenza vaccine
ffectiveness.
In conclusion, this study showed that IIV3-HD may  be more
mmunogenic than IIV3-SD in the 50–64 year age group and there-
ore might address the problem of immunosenescence. In addition,
he results suggest that IIV3-HD can be administered safely in this
ge group, although a larger population would be needed to detect
ny uncommon or rare events. As inﬂuenza is a signiﬁcant bur-
en for this age group, IIV3-HD might have an important public
ealth impact by providing improved protection against inﬂuenza
ompared to standard-dose vaccines.
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